Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

Sonneveld P., Moreau P., Dimopoulos M. A., Quach H., Ho P. J., BEKSAÇ M., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024 (SCI-Expanded, Scopus)

• Publication Type: Article / Abstract
• Publication Date: 2024
• Journal Name: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
• Ankara University Affiliated: Yes